HRT and exercise: Effects on bone density, muscle strength and lipid metabolism. A placebo controlled 2-year prospective trial on two estrogen-progestin regimens in healthy postmenopausal women

Maturitas

Volumn 26, Issue 2, 1997, Pages 139-149

  Heikkinen, Jorma ^a   Kyllönen, Eero ^b   Kurttila Matero, Eeva ^a   Wilén Rosenqvist, Gunilla ^c   Lankinen, Kari S ^c   Rita, Heli ^c   Väänänen, H Kalervo ^b  

^a OULU DEACONESS INSTITUTE   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c ORION CORPORATION   (Finland)

Author keywords

estradiol valerate; lipid metabolism; medroxyprogesterone acetate; muscle strength; osteoporosis; postmenopausal women; quarterly progestin

Indexed keywords

ESTROGEN; GESTAGEN; PLACEBO;

ADULT; ARTICLE; BONE DENSITY; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID METABOLISM; MAJOR CLINICAL STUDY; MUSCLE STRENGTH; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; CHOLESTEROL; CHOLESTEROL, LDL; CLIMACTERIC; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); EXERCISE THERAPY; FEMALE; FEMUR; HUMANS; ISOMETRIC CONTRACTION; LIPID METABOLISM; LIPIDS; LUMBAR VERTEBRAE; MEDROXYPROGESTERONE 17-ACETATE; MENOPAUSE; MIDDLE AGED; MUSCLE CONTRACTION; MUSCLE, SKELETAL; OSTEOPOROSIS, POSTMENOPAUSAL; PLACEBOS; POSTMENOPAUSE; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES;

EID: 0031104651     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(96)01098-5     Document Type: Article

References (35)

1. [1] Gambrell RD, Jr. Update on hormone replacement therapy. Am Fam Physician 1992; 46 (Suppl. 5): 87S-96S.
2. [2] Barrett-Connor EL. The risks and benefits of long-term estrogen replacement therapy. Public Health Rep 1989; 104: 62-65.
3. [3] Mishell DR, Jr. Estrogen replacement therapy: an overview. Am J Obstet Gynecol 1989; 161: 1825-1827.
4. [4] Smith R, Judd JWW. Hormone replacement therapy: a review. J Drug Dev 1992; 4: 235-244.
5. [5] Tosteson AN. Hormone replacement therapy: benefit, risk and cost considerations. J Clin Pharmacol 1994; 34: 719-722.
6. [6] Whitcroft SI, Stevenson JC. Hormone replacement therapy: risks and benefits. Clin Endocrinol 1992; 36: 15-20.
7. [7] Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-1037.
8. [8] Seeley DG, Cauley JA, Grady D, Browner WS, Nevitt MC, Cummings SR. Is postmenopausal estrogen therapy associated with neuromuscular function or falling in elderly women? Study of Osteoporotic Fractures Research Group. Arch Intern Med 1995; 155: 293-299.
9. [9] Heinonen A, Oja P, Kannus P, et al. Bone mineral density in female athletes representing sports with different loading characteristics of the skeleton. Bone 1995; 17: 197-203.
10. [10] Gleeson PB, Protas E, LeBlanc A, Scheider VS, Evans HJ. Effects of weight lifting on bone mineral density in premenopausal women. J Bone Miner Res 1990; 5: 153-158.
11. [11] Sinaki M. Exercise and osteoporosis. Arch Phys Med Rehabil 1989; 70: 220-229.
12. [12] Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976; 85: 447-452.
13. [13] Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease [see comments]. N Engl J Med 1989; 321: 641-646.
14. [14] Zavaroni I, Bonora E, Pagliara M, et al. Risk factors for coronary artery disease in healthy persons with hyperinsulinemia and normal glucose tolerance [see comments]. N Engl J Med 1989; 320: 702-706.
15. [15] Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-1109.
16. [16] Hirvonen E, Mälkönen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304: 560-563.
17. [17] Barentsen R, Groeneveld FP, Bareman FP, Hoes AW, Dokter HJ, Drogendijk AC. Women's opinion on withdrawal bleeding with hormone replacement therapy. Eur J Obstet Gynecol Reprod Biol 1993; 51: 203-207.
18. [18] Staland B. Continuous treatment with a combination of estrogen and gestagen - a way of avoiding endometrial stimulation. Clinical experiences with Kliogest®. Acta Obstet Gynecol Scand 1985; 131: 29-35.
19. [19] Hirvonen E, Salmi T, Puolakka J, et al. Can progestin be limited to every third month only in postmenopausal women taking estrogen? Maturitas 1995; 21: 39-44.
20. [20] Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 1994; 83: 693-700.
21. [21] Aitken RC. Measurement of feelings using visual analogue scales. Proc R Soc Med 1969; 62: 989-993.
22. [22] Kröger H, Heikkinen J, Laitinen K, Kotaniemi A. Dual-energy x-ray absorptiometry in normal women: a cross-sectional study of 717 Finnish volunteers. Osteoporosis Int 1992; 2: 135-140.
23. [23] Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
24. [24] Kyllonen ES, Väänänen HK, Heikkinen JE, Kurttila-Matero E, Martikkala V, Vanharanta JHV. Comparison of muscle strength and bone mineral density in healthy postmenopausal women. Scand J Rehab Med 1991; 23: 153-157.
25. [25] Wyss R, Vassilakos P, Riotton G. Eme neue Aspirationsmethode mit PISTOLET. Geburtshilfe Frauenheilkd 1975; 35: 846-853.
26. [26] Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994; 40: 671-677.
27. [27] Stevenson JC, Hillard TC, Lees B, Whitcroft SI, Ellerington MC, Whitehead MI. Postmenopausal bone loss: does HRT always work? Int J Fertil Menopausal Stud 1993; 38: 88-91.
28. [28] Castelo-Branco C, Martinez de Osaba MJ, Pons F, Gonzalez-Merlo J. The effect of hormone replacement therapy on postmenopausal bone loss. Eur J Obstet Gynecol Reprod Biol 1992; 44: 131-136.
29. [29] Christiansen C. Hormonal prevention and treatment of osteoporosis-state of the art 1990. J Steroid Biochem Mol Biol 1990; 37: 447-449.
30. [30] Holland EF, Leather AT, Studd JW. The effect of 25 mg percutaneous estradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994; 83: 43-46.
31. [31] McNeeley SG, Jr, Schinfeld JS, Stovall TG, Ling FW, Buxton BH. Prevention of osteoporosis by medroxyprogesterone acetate in postmenopausal women. Int J Gynaecol Obstet 1991; 34: 253-236.
32. [32] Naessén T, Persson I, Adami H-O, Bergstrom R, Bergkvist L. Hormone replacement therapy and the risk for first hip fracture. A prospective, population-based cohort study. Ann Intern Med 1990; 113: 95-103.
33. [33] Peng Z, Tuukkanen J, Vaananen HK. Exercise can provide protection against bone loss and prevent the decrease in mechanical strength of femoral neck in ovariectomized rats. J Bone Miner Res 1994; 9: 1559-1564.
34. [34] Marslew U, Rus BJ, Christiansen C. Desogestrel in hormone replacement therapy: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding. Eur J Clin Invest 1991; 21: 601-607.
35. [35] Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. [see comments]. J Am Med Assoc 1995; 273: 199-208.